BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

963 related articles for article (PubMed ID: 14707283)

  • 21. p14ARF induces the relocation of HDM2 and p53 to extranucleolar sites that are targeted by PML bodies and proteasomes.
    Kashuba E; Mattsson K; Klein G; Szekely L
    Mol Cancer; 2003 Mar; 2():18. PubMed ID: 12685933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation.
    Stommel JM; Wahl GM
    EMBO J; 2004 Apr; 23(7):1547-56. PubMed ID: 15029243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.
    Zhang Z; Wang H; Li M; Agrawal S; Chen X; Zhang R
    J Biol Chem; 2004 Apr; 279(16):16000-6. PubMed ID: 14761977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation.
    Zaika A; Marchenko N; Moll UM
    J Biol Chem; 1999 Sep; 274(39):27474-80. PubMed ID: 10488081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation.
    Zilfou JT; Hoffman WH; Sank M; George DL; Murphy M
    Mol Cell Biol; 2001 Jun; 21(12):3974-85. PubMed ID: 11359905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.
    Xirodimas DP; Stephen CW; Lane DP
    Exp Cell Res; 2001 Oct; 270(1):66-77. PubMed ID: 11597128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53.
    Zhang Y; Xiong Y
    Mol Cell; 1999 May; 3(5):579-91. PubMed ID: 10360174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization.
    Kurki S; Latonen L; Laiho M
    J Cell Sci; 2003 Oct; 116(Pt 19):3917-25. PubMed ID: 12915590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.
    Heessen S; Leonchiks A; Issaeva N; Sharipo A; Selivanova G; Masucci MG; Dantuma NP
    Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1532-7. PubMed ID: 11805282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation.
    Itahana K; Bhat KP; Jin A; Itahana Y; Hawke D; Kobayashi R; Zhang Y
    Mol Cell; 2003 Nov; 12(5):1151-64. PubMed ID: 14636574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of p53 degradation via MDM2-mediated ubiquitylation and the ubiquitin-proteasome system during reperfusion after stroke: role of oxidative stress.
    Saito A; Hayashi T; Okuno S; Nishi T; Chan PH
    J Cereb Blood Flow Metab; 2005 Feb; 25(2):267-80. PubMed ID: 15678128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.
    Fang S; Jensen JP; Ludwig RL; Vousden KH; Weissman AM
    J Biol Chem; 2000 Mar; 275(12):8945-51. PubMed ID: 10722742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53.
    Rajendra R; Malegaonkar D; Pungaliya P; Marshall H; Rasheed Z; Brownell J; Liu LF; Lutzker S; Saleem A; Rubin EH
    J Biol Chem; 2004 Aug; 279(35):36440-4. PubMed ID: 15247280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability and ubiquitination of the tumor suppressor protein p53.
    Jardine LJ; Maki CG
    Methods Mol Biol; 2003; 223():27-38. PubMed ID: 12777718
    [No Abstract]   [Full Text] [Related]  

  • 35. Dynamics in the p53-Mdm2 ubiquitination pathway.
    Brooks CL; Gu W
    Cell Cycle; 2004 Jul; 3(7):895-9. PubMed ID: 15254415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
    Swaroop M; Sun Y
    Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts.
    Gentiletti F; Mancini F; D'Angelo M; Sacchi A; Pontecorvi A; Jochemsen AG; Moretti F
    Oncogene; 2002 Jan; 21(6):867-77. PubMed ID: 11840332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells.
    Kraus A; Neff F; Behn M; Schuermann M; Muenkel K; Schlegel J
    Int J Cancer; 1999 Mar; 80(6):930-4. PubMed ID: 10074928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation.
    Okada Y; Osada M; Kurata S; Sato S; Aisaki K; Kageyama Y; Kihara K; Ikawa Y; Katoh I
    Exp Cell Res; 2002 Jun; 276(2):194-200. PubMed ID: 12027449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bivalent binding of p14ARF to MDM2 RING and acidic domains inhibits E3 ligase function.
    Kowalczyk D; Nakasone MA; Smith BO; Huang DT
    Life Sci Alliance; 2022 Aug; 5(12):. PubMed ID: 35944929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.